Lates News

date
21/04/2026
According to a report released by Guotai Junan Securities on April 21st, they have given a "Buy" rating to Pharmaron (000739.SZ). The reasons for this rating include: 1) Active contraction of raw materials, double increase in CDMO revenue gross margin; 2) Significant increase in gross margin in Q1 compared to the same period last year. (Daily Economic News)
Latest
See all latestmore